Lemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases
The standard review of the receptor family behind many cancer drugs, explaining how growth factor receptors such as EGFR and HER2 switch on when they pair up, how mutations lock them on in cancer, and how inhibitors turn them off.
Overview
Lemmon and Schlessinger surveyed the 58 human receptor tyrosine kinases in 20 subfamilies, describing how ligand binding drives receptor dimerisation and trans-autophosphorylation, the structural diversity of activation mechanisms across families, and the intracellular pathways (RAS-MAPK, PI3K-AKT, PLC-gamma and STAT) that carry the signal. They explained how overexpression, amplification, point mutations and fusions deregulate these receptors in cancer and how antibodies and small-molecule kinase inhibitors exploit the same mechanisms, with resistance mutations as the predictable consequence.
- Humans have 58 receptor tyrosine kinases in 20 subfamilies, activated by ligand-induced dimerisation and trans-autophosphorylation with family-specific mechanisms.
- Signals propagate through RAS-MAPK, PI3K-AKT, PLC-gamma and STAT pathways and are shaped by negative feedback and endocytosis.
- Cancers deregulate RTKs by amplification, mutation and fusion; therapeutic antibodies and kinase inhibitors target the receptors and select for resistance mutations.
Almost every targeted therapy on this site, from trastuzumab and EGFR inhibitors to ALK, MET, RET and FGFR drugs, acts on the receptors this review describes. It is the mechanistic background for understanding both why these drugs work and why resistance mutations arise.
- A review; structural details for several families have been refined since.
- Does not cover the clinical trials of the drugs it explains.
Similar pages
not linked directly; found by shared links- CompanyImagene AI
- TreatmentJS111
- TermGrowth factor
Shares Signalling pathway, MET, EGFR.
- TreatmentTQB2922
- TermOn-target resistance mutations (gatekeeper, solvent-front, compound)
Shares Tyrosine kinase inhibitor (TKI), ALK, EGFR.
- TermMET amplification (bypass resistance)
Shares MET, Receptor tyrosine kinase activation, EGFR.
- CompanyLucence
- TreatmentTQB6411